Food allergy company Alladapt raises $60M series C led by Viehbacher's Gurnet Point

With $60 million in a new series C round, Alladapt will test its broad-spectrum immunotherapy approach to treat a broad swath of food allergies in its first clinical trial beginning this year.

Gurnet Point Capital joined a syndicate of family offices in the round, taking two seats on Alladapt Immunotherapeutics Inc.'s board aside founding CEO Ashley Dombkowski. Representing the firm are Christopher Viehbacher, a former CEO of Sanofi (Euronext:SAN; NASDAQ:SNY); and Sophie Kornowski, who was an EVP at Roche (SIX:ROG; OTCQX:RHHBY)...